IQVIA (NYSE:IQV) Price Target Cut to $165.00 by Analysts at Barclays

IQVIA (NYSE:IQV - Free Report) had its price target decreased by Barclays from $170.00 to $165.00 in a report released on Wednesday, MarketBeat.com reports. Barclays currently has an equal weight rating on the medical research company's stock.

IQV has been the subject of several other research reports. JPMorgan Chase & Co. decreased their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Citigroup lowered their price objective on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $231.71.

IQVIA Trading Down 2.9 %

IQVIA stock traded down $4.39 during mid-day trading on Wednesday, hitting $148.90. 1,677,229 shares of the stock were exchanged, compared to its average volume of 1,468,618. The stock has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 1.99 and a beta of 1.34. IQVIA has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm's fifty day simple moving average is $163.91 and its two-hundred day simple moving average is $188.53.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.54 earnings per share. Analysts forecast that IQVIA will post 10.84 EPS for the current year.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after acquiring an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of IQVIA by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after purchasing an additional 77,981 shares during the period. Invesco Ltd. boosted its holdings in shares of IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after buying an additional 59,426 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.